Business Wire

Lenovo Integrates AI and Robotics to Deliver Smarter Retail Solutions

Share

Lenovo today introduced three new retail solutions that combine the best of robotics and artificial intelligence technologies. Premiering at NRF 2025 in New York City, each solution has been field-tested and proven in commercial settings.

Lenovo Retail Content Management Services enables retailers to create, schedule and display digital content across screens store-wide, streamlining multimedia content management and enabling real-time updates and targeted messaging to drive awareness, interest and incremental sales. The complete solution comprises all hardware and software needed, and can be deployed, maintained and managed across multiple locations globally.

A leading food and beverage chain has deployed this content management service across 100+ stores and achieved substantial cost savings from dynamically managed promotional campaigns, reduced use of paper marketing materials, and reduced manpower needed to manage both campaigns and devices.

Lenovo Retail Robotics with Yunji offers automated, independent deliveries of food, guest supplies, room services, and small packages to customers in hotels and malls. By integrating software and services with modular robots, the solution aims to enhance customer satisfaction, improve logistics efficiency, and enable smarter resource management.

This is an advancement to traditional retail robots in three ways. First, this modular design of the robot enables easy customization to a wide range of applications, unlike other robots that are locked into performing a single task. Second, AI, navigation and vision recognition enable high-quality interactions with customers that, combined with reduced delivery times, enable increased customer satisfaction. Third, it collects data as it works, enabling an AI-driven feedback loop that can be integrated into the supply chain, customer service and merchandising decision-making platforms.

The robotics solution, launched in partnership with Yunji Technology, has proven itself in real-world settings. Deployed in a 400-room hotel, for example, it handled more than 90% of guest requests and takeout services, which greatly saved on manpower and time while increasing sales revenue by 20%. Yunji’s robotics solutions are also currently deployed by more than 30,000 hotels, including those of Hilton Hotels & Resorts, Huazhu Group, InterContinental Hotels Group, Jinjiang Group, and Marriott Hotels & Resorts.

“While there is a lot of hype around AI and other technologies, examples of deployment in practical solutions that deliver measurable business outcomes is much rarer,” said Lawrence Yu, General Manager of Global Retail Solutions at Lenovo. “Today’s retailers have never faced greater challenges and have never needed technology to work for them more. Lenovo’s track record in the retail industry, working with some of the world’s biggest name retailers, means we can design, deploy and manage cutting-edge retail and hospitality solutions with low CapEx and high confidence.”

Meeting the AI challenge in retail

Deploying complex IT such as AI securely and responsibly and with maximized demonstrable return on investment remains a significant challenge for businesses in the retail sector.

Lenovo AI Fast Start addresses this challenge and helps retailers prove the business value of use cases on personal AI, enterprise AI and public AI platforms within weeks. It gives access to AI assets, experts and partners that will help retailers rapidly build a Gen AI use case solution securely with their own data and tailor it to their unique needs, speeding progress to full implementation.

A range of additional Lenovo TruScale as a Service offerings enable deployment of AI at scale, with speed and flexibility – and low CapEx costs. Lenovo TruScale Device as a Service (DaaS) provides a comprehensive AI devices portfolio and frees up valuable IT resources with a predictable, scalable subscription-based model. TruScale DaaS allows for quicker upgrades without upfront costs.

Lenovo TruScale Infrastructure as a Service (IaaS) combines the advantages of on-premises infrastructure with the flexibility of a cloud-like experience. Lenovo offers retailers tailored solutions for hybrid and multi-cloud environments, infinite storage, and high-performance computing (HPC). Lenovo’s new TruScale GPU as a Service offering enhances TruScale for HPC with advanced workload orchestration and usage metering, ensuring availability and maximizing productivity of AI-critical GPU resources.

“Although global retail sales are projected to recover in 2025, low consumer confidence is slated to continue plaguing the industry. It behooves retailers to capture this growth opportunity, by optimizing costs and boosting customer satisfaction with AI,” said Lawrence Yu. “Through relying on Lenovo’s deep retail expertise, our industry-leading, scalable hybrid AI approach, and our ability to deliver globally, today’s retailer can considerably improve their chances of sustainable success.”

Visit Lenovo at NRF 2025 exhibiting at booths #3665 and #3877.

For more information on Lenovo Retail Solutions, please visit https://techtoday.lenovo.com/us/en/solutions/retail.

About Lenovo

Lenovo is a US$57 billion revenue global technology powerhouse, ranked #248 in the Fortune Global 500, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company with a full-stack portfolio of AI-enabled, AI-ready, and AI-optimized devices (PCs, workstations, smartphones, tablets), infrastructure (server, storage, edge, high performance computing and software defined infrastructure), software, solutions, and services. Lenovo’s continued investment in world-changing innovation is building a more equitable, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992) (ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250110810803/en/

Contacts

Zeno Group for Lenovo: lenovossg@zenogroup.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in

Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release

Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release

Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye